S Ozawa

Publications (2)6 Total impact

• Article: Secondary solid tumors after allogeneic hematopoietic SCT in Japan.

  A Yokota, S Ozawa, T Masanori, H Akiyama, K Ohshima, Y Kanda, S Takahashi, T Mori, C Nakaseko, M Onoda, K Kishi, N Doki, N Aotsuka, H Kanamori, A Maruta, H Sakamaki, S Okamoto
  [show abstract] [hide abstract]
  ABSTRACT: To evaluate the incidence and risk factors for secondary solid tumors in Japan after allogeneic hematopoietic SCT (allo-HSCT), 2062 patients who had received allo-HSCT between 1984 and 2005 were retrospectively analyzed. Twenty-eight patients who developed 30 solid tumors were identified a median of 5.6 years after transplantation. The risk for developing tumors was 2.16-fold higher than that of the age- and sex-adjusted general population. The cumulative incidence of solid tumors at 10 years after allo-HSCT was 2.4%. The risk was significantly higher for tumors of the skin, oral cavity and esophagus (standard incidental ratio 40.23, 35.25 and 10.73, respectively). No increase in gastric, colon or lung cancer, despite being the most prevalent neoplasm in the Japanese, was observed. In multivariate analysis, occurrence of chronic GVHD and malignant lymphoma as a primary disease was associated with a higher risk for developing solid tumors. Eighteen patients are still alive, and their 5-year probability of survival since diagnosis of solid tumors is 59.7%. Our data suggest that the incidence and risk factors of secondary solid tumors in Japanese allo-HSCT recipients are comparable to those reported in Western countries and emphasize that the early detection of solid tumors has a crucial role in improving OS.
  Bone marrow transplantation 02/2011; 47(1):95-100. · 3.00 Impact Factor
• Article: Fasciitis and myositis: an analysis of muscle-related complications caused by chronic GVHD after allo-SCT.

  K Oda, C Nakaseko, S Ozawa, M Nishimura, Y Saito, F Yoshiba, T Yamashita, H Fujita, H Takasaki, H Kanamori, A Maruta, H Sakamaki, S Okamoto
  [show abstract] [hide abstract]
  ABSTRACT: The muscle-related complications of fasciitis and myositis, caused by chronic GVHD after Allo-SCT are relatively rare, but at times will severely impair a patient's quality of life (QOL). We performed a retrospective analysis in Japanese Allo-SCT recipients to identify the incidence, risk factors and clinical features of fasciitis and myositis. In 1967 patients who underwent Allo-SCT between January 1994 and March 2005 and survived beyond 90 days post transplantation, eight patients developed fasciitis and nine patients developed myositis, with a 5-year cumulative incidence of 0.55% and 0.54%, respectively. The median time from SCT to the development of fasciitis and myositis was 991 and 660 days, respectively. PBSCT was a risk factor for developing fasciitis, but no risk factors were found for myositis. The response to immunosuppressive treatment was better in patients with myositis than fasciitis, and the overall survival after developing these symptoms was better in patients with myositis than those with fasciitis. An early diagnosis by a biopsy, which includes fascia and muscle or magnetic resonance imaging (MRI) and prompt treatment may be important to prevent an impairment of the patient's QOL with persistent disability.
  Bone marrow transplantation 10/2008; 43(2):159-67. · 3.00 Impact Factor